Literature DB >> 16877598

Two-stage revision of infected total knee replacements using articulating cement spacers and short-term antibiotic therapy.

W J Hart1, R S Jones.   

Abstract

We present a series of 48 patients with infected total knee replacements managed by the use of articulating cement spacers and short-term parenteral antibiotic therapy in the postoperative period. All patients had microbiological and/or histological confirmation of infection at the first stage of their revision. They all underwent re-implantation and had a mean follow-up of 48.5 months (26 to 85). Infection was successfully eradicated in 42 of the 48 patients (88%). Six had persistent infection which led to recurrence of symptoms and further surgery was successful in eliminating infection in four patients. These rates of success are similar to those of other comparable series. We conclude that protracted courses of intravenous antibiotic treatment may not be necessary in the management of the infected total knee replacement. In addition, we analysed the microbiological, histological and serological results obtained at the time of re-implantation of the definitive prosthesis, but could not identify a single test which alone would accurately predict a successful outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877598     DOI: 10.1302/0301-620X.88B8.17445

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  32 in total

Review 1.  Two-stage revision of septic knee prosthesis with articulating knee spacers yields better infection eradication rate than one-stage or two-stage revision with static spacers.

Authors:  C L Romanò; L Gala; N Logoluso; D Romanò; L Drago
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-01-21       Impact factor: 4.342

2.  [Hip joint infections - Results of a questionnaire among 28 university orthopedic departments].

Authors:  K Anagnostakos; D Kohn
Journal:  Orthopade       Date:  2011-09       Impact factor: 1.087

3.  The use of spacers (static and mobile) in infection knee arthroplasty.

Authors:  Luca Mazzucchelli; Federica Rosso; Antongiulio Marmotti; Davide Edoardo Bonasia; Matteo Bruzzone; Roberto Rossi
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

4.  Assessing the gold standard: a review of 253 two-stage revisions for infected TKA.

Authors:  Tahir Mahmud; Matthew C Lyons; Douglas D Naudie; Steven J Macdonald; Richard W McCalden
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

5.  Does Change in ESR and CRP Guide the Timing of Two-stage Arthroplasty Reimplantation?

Authors:  Jeffrey B Stambough; Brian M Curtin; Susan M Odum; Michael B Cross; J Ryan Martin; Thomas K Fehring
Journal:  Clin Orthop Relat Res       Date:  2019-02       Impact factor: 4.176

6.  [Dynamic versus static cement spacer in periprosthetic knee infection: A meta-analysis].

Authors:  Mustafa Citak; Musa Citak; Daniel Kendoff
Journal:  Orthopade       Date:  2015-08       Impact factor: 1.087

7.  [C-reactive protein. An independent risk factor for the development of infection after primary arthroplasty].

Authors:  T Pfitzner; D Krocker; C Perka; G Matziolis
Journal:  Orthopade       Date:  2008-11       Impact factor: 1.087

Review 8.  Functional outcomes of acutely infected knee arthroplasty: a comparison of different surgical treatment options.

Authors:  Ivan Dzaja; James Howard; Lyndsay Somerville; Brent Lanting
Journal:  Can J Surg       Date:  2015-12       Impact factor: 2.089

9.  Direct exchange endoprosthetic reconstruction with tumour prosthesis for periprosthetic knee infection associated with segmental bone defects.

Authors:  Manjunath Ramappa; Ian McMurtry; Andrew Port
Journal:  Strategies Trauma Limb Reconstr       Date:  2010-01-12

Review 10.  Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach.

Authors:  Esa Jämsen; Ioannis Stogiannidis; Antti Malmivaara; Jorma Pajamäki; Timo Puolakka; Yrjö T Konttinen
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.